Natixis Buys 32,396 Shares of Thermo Fisher Scientific Inc. $TMO

Natixis increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 127.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 57,783 shares of the medical research company’s stock after acquiring an additional 32,396 shares during the quarter. Natixis’ holdings in Thermo Fisher Scientific were worth $23,429,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $2,264,615,000. Soundwatch Capital LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $807,713,000. Flossbach Von Storch SE lifted its position in shares of Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after buying an additional 1,314,182 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Thermo Fisher Scientific by 84.6% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,210,954 shares of the medical research company’s stock valued at $490,993,000 after acquiring an additional 555,018 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Thermo Fisher Scientific by 29.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after acquiring an additional 514,399 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TMO shares. Leerink Partners upped their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. increased their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Citigroup boosted their target price on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $612.95.

Thermo Fisher Scientific Trading Down 0.9%

NYSE TMO opened at $567.87 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $561.82 and a 200 day simple moving average of $487.30. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a market capitalization of $213.35 billion, a P/E ratio of 32.81, a PEG ratio of 4.19 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the prior year, the business posted $5.28 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This represents a 7.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the completion of the sale, the executive vice president directly owned 14,367 shares in the company, valued at $8,360,731.98. This trade represents a 32.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.